Navigation Links
Data From Phase II Trial of Prolor Biotech's Long-acting Human Growth Hormone Presented at Endo 2012
Date:6/26/2012

t forward-looking statements involve risks and uncertainties that may affect PROLOR's business and prospects, including the risks that PROLOR may not succeed in generating any revenues or developing any commercial products, including any long-acting versions of human growth hormone, erythropoietin, interferon beta, GLP-1 and other products; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from Israel's Office of the Chief Scientist is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The for
'/>"/>
SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Penn researchers study of phase change materials could lead to better computer memory
2. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
3. BioPharm Systems Launches Services to Help Phase I Clinics Implement Oracle Health Sciences LabPas
4. Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
5. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
6. Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
7. Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
8. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy
9. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
10. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer
11. Xention Reports Positive Phase 1 Data for New Atrial Fibrillation Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 6, 2015  Approximately 1% of the population inherits ... chromosomes. These individuals are three times more likely to ... one of the nation,s leading medical journals by researchers ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... causes roseola (also known as "sixth disease") and occasional ...
(Date:7/6/2015)... Medical, Inc. ("Viveve") (OTCQB: VIVMF), a company focused on women,s health, ... Officer, and Scott Durbin , Viveve,s Chief Financial Officer, ... , , , DATE:    , , , Thursday, ... , , , 12:15 PM EDT , , ... ,    This ...
(Date:7/3/2015)... (PRWEB) , ... July 03, ... ... company providing industry-leading products for use in applications such as animal waste ... wastewater treatment plants and restaurant kitchen settings, announced today that it will ...
(Date:7/3/2015)... WIEN , July 3, 2015 /PRNewswire/ ... fram till 22 september 2015 på  http://www.openinnovationinscience.at ... Open Innovation in Science" som hålls i ... Enligt en färsk undersökning med internationella forskare ... Gesellschaft (LBG) är hälsovetenskapens två största utmaningar ...
Breaking Biology Technology:Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3Viveve to Webcast Live at VirtualInvestorConferences.com 2Viveve to Webcast Live at VirtualInvestorConferences.com 3DryLet to Highlight Benefits of Patented ManureMagic™ at North American Manure Expo in Chambersburg, PA July 14-15, 2015 2Lansering av världens första program för öppen innovation för att utbilda forskare 2Lansering av världens första program för öppen innovation för att utbilda forskare 3
... Calif., Dec. 20 Ardea Biosciences,Inc. (Nasdaq: ... and development of,small-molecule therapeutics for the treatment of ... it has entered into a,securities purchase agreement with ... the private placement of approximately 3.0,million newly issued ...
... Dec. 20 ISTO Technologies, Inc., a privately,held orthobiologic ... Finance Forum in San Francisco, CA from January 7-8, ... will present on,Tuesday, January 8th at 11:00 a.m. Pacific ... St. Information about the OneMedPlace Finance Forum may,be found ...
... -- China Technology,Development Group Corporation (Nasdaq: CTDC, "the ... energy products and solutions focusing on,solar energy business ... step in its strategic plan to focus the ... of solar energy., On December 18, 2007, ...
Cached Biology Technology:Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3CTDC Announces the Disposal of Non-core Business 2
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
(Date:6/25/2015)... -- TAKE Solutions Ltd., a global business technology solutions provider, ... and Trademark Office (USPTO) for its "Method for Optimizing ... Accelerators to reduce the time taken to standardize trial ... the accelerators), thus reducing time to market. ... heart of the patented Clinical Data Standardization Process are ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Latin America Biomedical Sensors Market Report 2015-2020 2TAKE Solutions Awarded Patent By USPTO 2
... 2008 -- Scientists were surprised with findings of a recent ... small contained areas actually need broad, landscape level conservation to ... than any other time in human history, the findings of ... Letters provides new insight into how to improve protection ...
... Copenhagen has studied human remains found in two ancient Danish ... a man who appears to be of arabian origin. The ... years ago as they are today and indicate greater mobility ... also suggest that people in the Danish iron age did ...
... known like President Bush and musician Neil Young, but Philadelphian ... has a new species named after him. , Gallagher was ... years before retiring in 2003. "They used to call me ... mail to the staff but also passed along the latest ...
Cached Biology News:New study reveals large scale conservation essential 2New study reveals large scale conservation essential 3New research refutes myth of pure Scandinavian race 2New research refutes myth of pure Scandinavian race 3New catfish species named for museum mail supervisor 2
... mass detection but not structural information ... spectrometer is ideally suited for high ... performance mass analysis. Typical applications ... detection, micro-satellite DNA characterization and polymer ...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
... an ideal small concentrator for the molecular ... removing water and organic solvents from a ... vials and round bottom flasks. Making it ... lab. ,The built-in special runs for working ...
Biology Products: